These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 36335649)

  • 21. Design, synthesis and in vitro antitumor evaluation of novel pyrazole-benzimidazole derivatives.
    Ren B; Liu RC; Ji K; Tang JJ; Gao JM
    Bioorg Med Chem Lett; 2021 Jul; 43():128097. PubMed ID: 33979690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of new 5-(2,6-dichlorophenyl)-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-7-carboxylic acids as p38α MAPK inhibitors: Design, synthesis, antitumor evaluation, molecular docking and in silico studies.
    El-Wakil MH; El-Dershaby HA; Ghazallah RA; El-Yazbi AF; Abd El-Razik HA; Soliman FSG
    Bioorg Chem; 2024 Apr; 145():107226. PubMed ID: 38377818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, molecular modeling, and biological evaluation of pyrazole-naphthalene derivatives as potential anticancer agents on MCF-7 breast cancer cells by inhibiting tubulin polymerization.
    Wang G; Liu W; Peng Z; Huang Y; Gong Z; Li Y
    Bioorg Chem; 2020 Oct; 103():104141. PubMed ID: 32750611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
    El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
    Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
    El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
    Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells.
    Xiong B; Chen S; Zhu P; Huang M; Gao W; Zhu R; Qian J; Peng Y; Zhang Y; Dai H; Ling Y
    Med Chem; 2019; 15(7):743-754. PubMed ID: 30147012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of purine-pyrazole hybrids incorporating thiazole, thiazolidinone or rhodanine moiety as 15-LOX inhibitors endowed with anticancer and antioxidant potential.
    Afifi OS; Shaaban OG; Abd El Razik HA; Shams El-Dine SEA; Ashour FA; El-Tombary AA; Abu-Serie MM
    Bioorg Chem; 2019 Jun; 87():821-837. PubMed ID: 30999135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
    Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
    Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel pyrazole-5-carboxamide and pyrazole-pyrimidine derivatives: synthesis and anticancer activity.
    Shi JB; Tang WJ; Qi XB; Li R; Liu XH
    Eur J Med Chem; 2015 Jan; 90():889-96. PubMed ID: 25554922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New benzimidazole based hybrids: Synthesis, molecular modeling study and anticancer evaluation as TopoII inhibitors.
    Nawareg NA; Mostafa AS; El-Messery SM; Nasr MNA
    Bioorg Chem; 2022 Oct; 127():106038. PubMed ID: 35870412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
    Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
    Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
    Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and
    Shehta W; Agili F; Farag B; Youssif S; Almehmadi SJ; Elfeky SM; El-Kalyoubi S
    Future Med Chem; 2023 Apr; 15(8):661-677. PubMed ID: 37125606
    [No Abstract]   [Full Text] [Related]  

  • 40. Design, synthesis, molecular docking and biological evaluation of 1,3,5-trisubstituted-1H-pyrazole derivatives as anticancer agents with cell cycle arrest, ERK and RIPK3- kinase activities.
    Boshta NM; Temirak A; El-Shahid ZA; Shafiq Z; Soliman AAF
    Bioorg Chem; 2024 Feb; 143():107058. PubMed ID: 38159496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.